Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent

  • Ecancermedicalscience. 2014 Jul 10;8:443. doi: 10.3332/ecancer.2014.443.
Pan Pantziarka  1 ,  Gauthier Bouche  2 ,  Lydie Meheus  2 ,  Vidula Sukhatme  3 ,  Vikas P Sukhatme  4
Affiliations
  • 1. Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium ; The George Pantziarka TP53 Trust, London KT1 2JP, UK.
  • 2. Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.
  • 3. GlobalCures, Inc, Newton, MA 02459, USA.
  • 4. GlobalCures, Inc, Newton, MA 02459, USA ; Beth Israel Deaconess Medical Centre and Harvard Medical School, Boston, MA 02215, USA.
PMID: 25075217 DOI: 10.3332/ecancer.2014.443
Abstract

Mebendazole, a well-known anti-helminthic drug in wide clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical studies across a number of different Cancer types. Significantly, there are also two case reports of anti-cancer activity in humans. The data are summarised and discussed in relation to suggested mechanisms of action. Based on the evidence presented, it is proposed that mebendazole would synergise with a range of Other drugs, including existing chemotherapeutics, and that further exploration of the potential of mebendazole as an anti-cancer therapeutic is warranted. A number of possible combinations with Other drugs are discussed in the Appendix.

Keywords
ReDO Project; anti-helminthic; cancer; drug repurposing; metronomic chemotherapy.
Products